Autonomic nervous system drugs

((2R,7As)-2-fluorohexahydro-1H-pyrrolizin-7a-yl)methanol.

((2R,7As)-2-fluorohexahydro-1H-pyrrolizin-7a-yl)methanol.

((2R,7As)-2-fluorohexahydro-1H-pyrrolizin-7a-yl)methanol.

((2R,7As)-2-fluorohexahydro-1H-pyrrolizin-7a-yl)methanol.

((2R,7As)-2-fluorohexahydro-1H-pyrrolizin-7a-yl)methanol.

((2R，3S，4S，5R，6R)-6-(((2S，3S，4S，5R)-3，4-Dihydroxy-2，5-bis(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3，4，5-trihydroxytetrahydro-2H-pyran-2-yl)methyl dodecanoate.

((5Z)-5-{1-[2-(3-CHLOROANILINO)-2-OXOETHYL]-2-OXO-1 2-DIHYDRO-3H-INDOL-3-YLIDENE}-4-OXO-2-THIOXO-1 3-THIAZOLIDIN-3-YL)ACETIC AC-

A selective agonist of the dopamine D1-like receptor (Ki = 1.9 nM) that demonstrates comparatively lower binding affinity for the dopamine D2, dopamine D3, serotonin 5-HT2A, and adrenergic &alpha2 receptors (Kis = 1,272, &gt10,000, 955, and 509

A selective agonist of the dopamine D1-like receptor (Ki = 1.9 nM) that demonstrates comparatively lower binding affinity for the dopamine D2, dopamine D3, serotonin 5-HT2A, and adrenergic &alpha2 receptors (Kis = 1,272, &gt10,000, 955, and 509

Molecular Formula: C36H40N4SO10 Molecular Weight: 720.8 MDL No.: MFCD09952659 Storage Temperature: Store at 0-8°C

(+)-Butaclamol hydrochloride is a D2DR inhibitor. Studies on rat striatal Homovanillic acid concentrations indicate that (+)-Butaclamol hydrochloride increases the concentration of this compound, via D2DR antagonism. In addition, these studies

(+)-Cevimeline hydrochloride hemihydrate ((+)-SNI-2011), a potent muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome./nIC50 value:/nTarget: mAChR The general pharmacol. properties of this drug on the